Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables: 2022-2024

Historic Receivables for Autolus Therapeutics (AUTL) over the last 3 years, with Dec 2024 value amounting to $1.4 million.

  • Autolus Therapeutics' Receivables was N/A to $33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.0 million, marking a year-over-year change of. This contributed to the annual value of $1.4 million for FY2024, which is 129.76% up from last year.
  • Autolus Therapeutics' Receivables amounted to $1.4 million in FY2024, which was up 129.76% from $625,000 recorded in FY2023.
  • Autolus Therapeutics' Receivables' 5-year high stood at $1.6 million during FY2022, with a 5-year trough of $625,000 in FY2023.
  • Over the past 3 years, Autolus Therapeutics' median Receivables value was $1.4 million (recorded in 2024), while the average stood at $1.2 million.
  • Per our database at Business Quant, Autolus Therapeutics' Receivables slumped by 59.83% in 2023 and then spiked by 129.76% in 2024.
  • Over the past 3 years, Autolus Therapeutics' Receivables (Yearly) stood at $1.6 million in 2022, then tumbled by 59.83% to $625,000 in 2023, then soared by 129.76% to $1.4 million in 2024.